Your browser doesn't support javascript.
loading
Understanding "Hybrid Immunity": Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines.
Epsi, Nusrat J; Richard, Stephanie A; Lindholm, David A; Mende, Katrin; Ganesan, Anuradha; Huprikar, Nikhil; Lalani, Tahaniyat; Fries, Anthony C; Maves, Ryan C; Colombo, Rhonda E; Larson, Derek T; Smith, Alfred; Chi, Sharon W; Maldonado, Carlos J; Ewers, Evan C; Jones, Milissa U; Berjohn, Catherine M; Libraty, Daniel H; Edwards, Margaret Sanchez; English, Caroline; Rozman, Julia S; Mody, Rupal M; Colombo, Christopher J; Samuels, Emily C; Nwachukwu, Princess; Tso, Marana S; Scher, Ann I; Byrne, Celia; Rusiecki, Jennifer; Simons, Mark P; Tribble, David; Broder, Christopher C; Agan, Brian K; Burgess, Timothy H; Laing, Eric D; Pollett, Simon D.
Afiliação
  • Epsi NJ; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Richard SA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA.
  • Lindholm DA; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Mende K; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA.
  • Ganesan A; Brooke Army Medical Center, Fort Sam Houston, Texas, USA.
  • Huprikar N; Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Lalani T; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Fries AC; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA.
  • Maves RC; Brooke Army Medical Center, Fort Sam Houston, Texas, USA.
  • Colombo RE; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Larson DT; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA.
  • Smith A; Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
  • Chi SW; Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
  • Maldonado CJ; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Ewers EC; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA.
  • Jones MU; Naval Medical Center Portsmouth, Portsmouth, Virginia, USA.
  • Berjohn CM; US Air Force School of Aerospace Medicine, Dayton, Ohio, USA.
  • Libraty DH; Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
  • Edwards MS; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • English C; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA.
  • Rozman JS; Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Mody RM; Madigan Army Medical Center, Joint Base Lewis McChord, Washington, USA.
  • Colombo CJ; Fort Belvoir Community Hospital, Fort Belvoir, Virginia, USA.
  • Samuels EC; Naval Medical Center San Diego, San Diego, California, USA.
  • Nwachukwu P; Naval Medical Center Portsmouth, Portsmouth, Virginia, USA.
  • Tso MS; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Scher AI; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA.
  • Byrne C; Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Rusiecki J; Womack Army Medical Center, Fort Bragg, North Carolina, USA.
  • Simons MP; Fort Belvoir Community Hospital, Fort Belvoir, Virginia, USA.
  • Tribble D; Tripler Army Medical Center, Honolulu, Hawaii, USA.
  • Broder CC; Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Agan BK; Naval Medical Center San Diego, San Diego, California, USA.
  • Burgess TH; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Laing ED; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA.
  • Pollett SD; Naval Medical Center San Diego, San Diego, California, USA.
Clin Infect Dis ; 76(3): e439-e449, 2023 02 08.
Article em En | MEDLINE | ID: mdl-35608504
ABSTRACT

BACKGROUND:

Comparison of humoral responses in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinees, those with SARS-CoV-2 infection, or combinations of vaccine/ infection ("hybrid immunity") may clarify predictors of vaccine immunogenicity.

METHODS:

We studied 2660 US Military Health System beneficiaries with a history of SARS-CoV-2 infection-alone (n = 705), vaccination-alone (n = 932), vaccine-after-infection (n = 869), and vaccine-breakthrough-infection (n = 154). Peak anti-spike-immunoglobulin G (IgG) responses through 183 days were compared, with adjustment for vaccine product, demography, and comorbidities. We excluded those with evidence of clinical or subclinical SARS-CoV-2 reinfection from all groups.

RESULTS:

Multivariable regression results indicated that vaccine-after-infection anti-spike-IgG responses were higher than infection-alone (P < .01), regardless of prior infection severity. An increased time between infection and vaccination was associated with greater post-vaccination IgG response (P < .01). Vaccination-alone elicited a greater IgG response but more rapid waning of IgG (P < .01) compared with infection-alone (P < .01). BNT162b2 and mRNA-1273 vaccine-receipt was associated with greater IgG responses compared with JNJ-78436735 vaccine-receipt (P < .01), regardless of infection history. Those with vaccine-after-infection or vaccine-breakthrough-infection had a more durable anti-spike-IgG response compared to infection-alone (P < .01).

CONCLUSIONS:

Vaccine-receipt elicited higher anti-spike-IgG responses than infection-alone, although IgG levels waned faster in those vaccinated (compared to infection-alone). Vaccine-after-infection elicits a greater humoral response compared with vaccine or infection alone; and the timing, but not disease severity, of prior infection predicted these post-vaccination IgG responses. While differences between groups were small in magnitude, these results offer insights into vaccine immunogenicity variations that may help inform vaccination timing strategies.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / COVID-19 Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Clin Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / COVID-19 Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Clin Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos